Ibn Sina Pharmaceutical PLC reported a 160% year-on-year rise in consolidated net profit in the July–September quarter, reflecting strong sales and improved operational efficiency.
The company posted consolidated revenue of Tk 372 crore, up 34.8% from Tk 276 crore in the same quarter last year, according to its latest financial disclosure. Group operating profit doubled to Tk 34 crore from Tk 17 crore a year earlier.
Rising administrative and selling expenses were offset by stronger sales, stable finance costs and higher other income, the filing showed. Consolidated earnings per share jumped to Tk 7.08 from Tk 2.72.
The company consolidates financials of its three subsidiaries — Ibn Sina Natural Medicine Ltd, Ibn Sina API Industry Ltd and Ibn Sina Polymer Industry Ltd.
Consolidated net asset value per share increased to Tk 132.67 as of September 30, 2025, from Tk 125.69 on June 30, 2025.
On a standalone basis, Ibn Sina Pharmaceutical recorded 51% year-on-year growth in net profit.
Standalone revenue rose 30% to Tk 331 crore in the quarter.
Earnings per share for the parent company increased to Tk 6.89 from Tk 4.55 in the same period last fiscal.
Ibn Sina shares rose over 5% to close at Tk 303.7 each on a weak trading day at the Dhaka Stock Exchange, making it the top gainer of the session.
